Document Detail

Follow-up of 452 totally implantable vascular devices in cystic fibrosis patients.
MedLine Citation:
PMID:  15065834     Owner:  NLM     Status:  MEDLINE    
The use and complications of totally implantable vascular access devices (TIVADs) were examined during multiple courses of antibiotics in cystic fibrosis (CF) patients. This retrospective study involved 36 CF centres. Risk factors for removal and septicaemia were sought by survival analysis of censored data. Multivariate Cox models were constructed with removal or septicaemia as the event and the characteristics of TIVADs as explanatory variables. TIVADs (n = 452) were implanted in 315 patients. The mean functional time per device was 32 +/- 25 months. Long-term complications occurred with 188 devices (42%); they consisted mainly of occlusion (21%, requiring removal in 77%), infection (9.3%, requiring removal in 851%; septicaemia in 7.3%; rate 0.3 per 1,000 days, Candida in 66%), and vascular thrombosis (4.7%, removal in 58%). Multivariate survival analysis showed that removal, whatever the reason, was associated with polyurethane (versus silicone) and routine use of the device for blood sampling (versus never). No risk factors, including heparin lock, were identified for septicaemia or for removal for obstruction. Totally implantable venous access devices appear to be safe and reliable for long-term intermittent venous access. Although retrospective, this study suggests that the characteristics of the material and blood sampling are risk factors for removal.
A Munck; S Malbezin; J Bloch; M Gerardin; M Lebourgeois; J Derelle; F Bremont; I Sermet; M R Munck; J Navarro
Related Documents :
21594234 - Effect of sodium ascorbate on tag formation in bleached enamel.
22376004 - The effect of repeated torque in small diameter implants with machined and premachined ...
19347564 - An algorithm for managing patients who have composix kugel ventral hernia mesh.
23343804 - Clinical and ultrastructural effects of different liners/restorative materials on deep ...
12420574 - Determination of the morphological irregularities in the middle and apical 1/3rd region...
9484144 - The effect of internal bevel on marginal leakage at the approximal surface of class 2 c...
Publication Detail:
Type:  Journal Article; Multicenter Study    
Journal Detail:
Title:  The European respiratory journal     Volume:  23     ISSN:  0903-1936     ISO Abbreviation:  Eur. Respir. J.     Publication Date:  2004 Mar 
Date Detail:
Created Date:  2004-04-06     Completed Date:  2004-06-17     Revised Date:  2013-05-23    
Medline Journal Info:
Nlm Unique ID:  8803460     Medline TA:  Eur Respir J     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  430-4     Citation Subset:  IM    
Dept of Paediatric Gastroenterology and Nutrition, Hospital Robert Debré, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Bacterial Agents / administration & dosage
Blood Specimen Collection
Catheters, Indwelling* / adverse effects
Cystic Fibrosis / therapy*
Focal Infection / epidemiology
Follow-Up Studies
Infusions, Intravenous
Parenteral Nutrition
Proportional Hazards Models
Retrospective Studies
Risk Factors
Sepsis / epidemiology
Thrombosis / epidemiology
Time Factors
Reg. No./Substance:
0/Anti-Bacterial Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of obesity upon genioglossus structure and function in obstructive sleep apnoea.
Next Document:  A short-term comparison of two methods of sputum expectoration in cystic fibrosis.